The combination of low capital investment, low cost
of goods, coupled with highly scalable manufacturing capability is
particularly important for many products and will enable the development
of new applications that are currently not achievable with conventional
fermenter based production technologies.
Of course, not all pharmaceuticals will be
appropriate, or will need to be made in plant systems. Application areas
that are thought likely to benefit most are:
Medicines that are required in very large
quantities e.g. monoclonal antibodies, some sub-unit vaccines, HIV
Medicines that can only be made in plants e.g.
secretory IgA antibodies - at present this major class of antibody
that is important for mucosal prevention of disease cannot be made efficiently
by any other means.
Medicines that are specifically designed for
production in plants e.g. recombinant immune complexes - with a
growing understanding of the mechanisms of protein production in
plants, has come the ability to engineer molecules with enhanced
principal advantages which plants can
offer need to be evaluated case by case when choosing the
best production system. Target molecules assessment of (clinical)
need and production feasibility will be reviewed within the
working group 3 (WG3). This WG3 is led by Dirk Bosch and Arjen Schots.
During the Action, a novel Molecular Farming database has been built up grouping
published and unpublished data. This database is searchable using queries like plant platform, expression
level etc. It can be reached through the following link:
http://mped.ab.wur.nl and is accessible to everyone interested.